- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT06952413
근심 뇌종염/만성 피로 증후군 (ME/CFS)에서 리툭시 맙의 효능 및 안전성에 대한 연구
근육질 뇌종염/만성 피로 증후군 (ME/CFS)에서 리툭시 맙 (유전 적 재조합)의 효능 및 안전성에 대한 탐색 적, 위약 대조, 이중 맹검, 이중 맹검, 2 상 연구.
The efficacy and safety of rituximab on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.
연구 개요
상세 설명
The efficacy and safety of rituximab (genetical recombination), a CD20 antibody, on ME/CFS symptoms after administration to patients with myalgic encephalomyelitis/chronic fatigue syndrome will be compared in an exploratory, placebo-controlled, double-blind fashion. In the subsequent secondary evaluation period, subjects who received rituximab in the primary evaluation period will receive placebo, and the timing and duration of rituximab's effect will be explored throughout the entire evaluation period. Subjects who received placebo during the primary evaluation period will receive rituximab during the secondary evaluation period to explore changes in endpoints before and after switching from placebo to rituximab in the same subjects.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Takami Ishizuka, PhD
- 전화번호: +081-42-341-2711
- 이메일: tmc-crso@ncnp.go.jp
연구 장소
-
-
Tokyo
-
Kodaira, Tokyo, 일본, 187-8551
- 모병
- National Center of Neurology and Psychiatry
-
연락하다:
- Takami Ishizuka, PhD
- 전화번호: +81-42-341-2711
- 이메일: tmc-crso@ncnp.go.jp
-
수석 연구원:
- Tomoko Okamoto, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Patients diagnosed with ME/CFS who meet the Canadian criteria by a physician.
- Patients with a severity score of 4 or higher on the Performance Status (PS) based ME/CFS severity classification by the Ministry of Health, Labour and Welfare Research Group
- Patients who are between 18 and 65 years of age at the time of obtaining written consent
- Patients who can be hospitalized (hospitalized from the day before administration and discharged the day after administration) at the time of the first dose of each of the primary and secondary evaluation periods
- Patients whose written consent has been obtained
Exclusion Criteria:
-
Patients with a history of severe hypersensitivity or anaphylactic reactions to components of rituximab or products derived from mouse protein
-
Patients whose cardiopulmonary function is judged by the treating physician to be not maintained
-
Patients complaining of fatigue that does not meet the diagnostic criteria for ME/CFS
-
Patients found to have other medical conditions that may cause symptoms
-
Patients who are pregnant, lactating, or have a positive pregnancy test (serum human chorionic gonadotropin test) at the time of enrollment
-
Patients with coexisting or pre-existing malignant tumors (excluding basal cell carcinoma of the skin and cervical dysplasia)
-
Patients with coexisting or pre-existing severe immune system diseases (excluding autoimmune diseases such as thyroiditis and type 1 diabetes)
-
Patients with a history of systemic immunosuppressive therapy (e.g., immunoglobulin therapy, azathioprine, cyclosporine, mycophenolate mofetil, etc.) within 1 year, a history of receiving drugs such as monoclonal antibodies acting on the immune system (e.g., anti-CD20 antibody products including rituximab), or a history of comorbidities requiring treatment with immunosuppressive drugs Patients with comorbidities requiring treatment with immunosuppressive agents (excluding treatment with low-dose steroids of 5 mg /day or less)
-
Patients who have started alternative medicine (reference: acupuncture, moxibustion, and Japanese warm therapy) within 12 weeks prior to the start of treatment with the investigational drug.
-
Patients with severe endogenous (primary) depression
-
Patients with a neutrophil count <1.5*103/microliter and platelet count <10.0*104/microliter on blood test
-
Patients with impaired renal function (serum creatinine level > 1.5 times the upper limit of the reference value at the institution)
-
Patients with impaired hepatic function (serum bilirubin, Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT) levels exceeding 1.5 times the upper limit of the reference value of the institution)
-
Patients infected with Human Immunodeficiency Virus (HIV)
-
Patients who test positive for at least one of Hepatitis B surface (HBs) antigen, HBs antibody, Hepatitis B core (HBc) antibody, or Hepatitis C virus (HCV) antibody.
However, patients who meet the following conditions (1) and (2) may be registered.
(i) Patients who are positive for HBs or HBc antibodies and whose HBV-DNA quantification is confirmed to be negative (less than detection sensitivity) and for whom appropriate monitoring, etc. can be conducted in accordance with the Guidelines for Hepatitis B Treatment edited by the Japan Society of Hepatology.
(ii) For patients with positive HCV antibody, when HCV-RNA quantification is negative (less than detection sensitivity)
-
Patients who do not have the ability to comply with the study protocol
-
Patients who have participated in other clinical trials or clinical studies (except for observational studies without intervention) within 16 weeks prior to obtaining consent
-
Other patients who are judged by the investigator or subinvestigator (hereinafter referred to as investigator) to be inappropriate to participate in this clinical trial.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 크로스오버 할당
- 마스킹: 네 배로
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
위약 비교기: 위약
|
Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods. |
|
활성 비교기: 리툭시 맙 (유전 적 재조합)
|
Subjects will be assigned to the rituximab pre-treatment group or placebo pre-treatment group and will receive the study drug (rituximab actual or rituximab placebo) intravenously four times at weekly intervals during the first three weeks of the primary and secondary evaluation periods. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Improvement rate
기간: From Baseline to the end of treatment at 24 weeks
|
Percentage of cases in which the severity score of ME/CFS based on PS by the MHLW research group improved by 1 or more compared to that before the start of study drug administration (week 0) |
From Baseline to the end of treatment at 24 weeks
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
MHLW-PS 기반 ME/CFS 심각도 점수가 각 평가 지점 (개선 속도)에서 1 개 이상으로 개선 된 환자의 백분율 (0 주).
기간: 기준선에서 4 주 간격으로 4 주 간격으로 48
|
기준선에서 4 주 간격으로 4 주 간격으로 48
|
|
|
조사 약물 치료가 시작되기 전 각 평가 지점에서 MHLW 연구 그룹에 의한 PS에 기초한 ME/CFS의 심각도 점수의 변화량 (0 주)
기간: 기준선에서 4 주 간격으로 4 주 간격으로 48
|
기준선에서 4 주 간격으로 4 주 간격으로 48
|
|
|
Proportion of awake time spent in supine position (%),Proportion of awake time spent in sitting position (%)
기간: At 4-week intervals from Baseline up to Week 48
|
Changes in proportions will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Duration of standing and activity (hours)
기간: At 4-week intervals from Baseline up to Week 48
|
Changes in time will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Fatigue during rest and lying position
기간: At 4-week intervals from Baseline up to Week 48
|
Patients will be asked to report the level of fatigue they feel even while lying down, and changes in their fatigue levels will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Records on exertion and Post-Exertional Malaise (PEM)
기간: At 4-week intervals from Baseline up to Week 48
|
Patients will be asked to describe the specific activities they perform and the exhaustion they experience afterward, and a summary table will be created. |
At 4-week intervals from Baseline up to Week 48
|
|
Assessment of fatigue during physical activity
기간: At 4-week intervals from Baseline up to Week 48
|
Patients will be asked to report the level of fatigue they experience during physical activity in daily life, and changes in fatigue levels will be aggregated. |
At 4-week intervals from Baseline up to Week 48
|
|
Evaluation based on Fatigue Score
기간: At 2-week intervals from Baseline up to Week 48
|
Patients will be asked to complete the Fatigue Score questionnaire, and changes in the score will be aggregated. |
At 2-week intervals from Baseline up to Week 48
|
|
SF-36
기간: At 12-week intervals from Baseline up to Week 48
|
Changes in scores obtained from the SF-36 questionnaire will be assessed to evaluate patients' quality of life. |
At 12-week intervals from Baseline up to Week 48
|
|
COMPASS31
기간: At 12-week intervals from Baseline up to Week 48
|
Changes in scores obtained from the COMPASS31 questionnaire will be assessed to evaluate patients' autonomic symptoms. |
At 12-week intervals from Baseline up to Week 48
|
|
Pittsburgh Sleep Quality Index (PSQI)
기간: At 12-week intervals from Baseline up to Week 48
|
Changes in scores obtained from the PSQI questionnaire will be assessed to evaluate patients' sleep quality. |
At 12-week intervals from Baseline up to Week 48
|
|
Pain intensity
기간: At 12-week intervals from Baseline up to Week 48
|
Pain intensity will be assessed using the Visual Analogue Scale (VAS) |
At 12-week intervals from Baseline up to Week 48
|
|
Grip strength
기간: At 12-week intervals from Baseline up to Week 48
|
Patients' grip strength will be measured, and changes in the measurements will be aggregated. |
At 12-week intervals from Baseline up to Week 48
|
|
Analysis of the gut microbiota
기간: At 24-week intervals from Baseline up to Week 48
|
samples collected from patients will be analyzed, and the composition of the gut microbiota will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Brain imaging evaluation (Magnetic Resonance Imaging (MRI) of the head, Single Photon Emission Computed Tomography (SPECT) of cerebral blood flow)
기간: At 24-week intervals from Baseline up to Week 48
|
Findings from imaging will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Immune biomarker analysis (qPCR)
기간: At 24-week intervals from Baseline up to Week 48
|
qPCR will be measured, and changes in their levels will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Immune biomarker analysis (anti-autonomic receptor antibody analysis)
기간: At 24-week intervals from Baseline up to Week 48
|
Quantify the level of anti-autonomic receptor antibodies will be measured, and changes in their levels will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Immune biomarker analysis (immune cell subfractionation analysis)
기간: At 24-week intervals from Baseline up to Week 48
|
The subsets of immune cells will be measured, and changes in the levels will be aggregated. |
At 24-week intervals from Baseline up to Week 48
|
|
Metabolome analysis
기간: At Baseline
|
A detailed characterization of the patients' metabolome at baseline will be conducted. |
At Baseline
|
|
Adverse events
기간: From Baseline up to Week 48
|
The number of adverse events will be aggregated. |
From Baseline up to Week 48
|
|
Vital signs (body temperature)
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
Summary statistics of vital signs will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
|
Vital signs (blood pressure)
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
Summary statistics of vital signs will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
|
Vital signs (pulse rate)
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
Summary statistics of vital signs will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 8, 12, 24, 25, 26, 27, 28, 32, 36, and 48
|
|
Serum immunoglobulins (IgG)
기간: At 4-week intervals from Baseline up to Week 48
|
Summary statistics of serum immunoglobulins will be calculated to monitor changes over time. |
At 4-week intervals from Baseline up to Week 48
|
|
Serum immunoglobulins (IgM)
기간: At 4-week intervals from Baseline up to Week 48
|
Summary statistics of serum immunoglobulins will be calculated to monitor changes over time. |
At 4-week intervals from Baseline up to Week 48
|
|
Serum immunoglobulins (IgA)
기간: At 4-week intervals from Baseline up to Week 48
|
Summary statistics of serum immunoglobulins will be calculated to monitor changes over time. |
At 4-week intervals from Baseline up to Week 48
|
|
Rituximab concentration of the blood plasma
기간: Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48
|
Rituximab concentration of the blood plasma |
Assessments will be conducted at baseline and at Weeks 1, 2, 3, 4, 12, 24, 25, 26, 27, 28, 36, and 48
|
|
Blood drug concentration Anti-Drug Antibody (ADA)
기간: Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.
|
Summary statistics of ADA will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 4, 12, 24, 28, 36, and 48.
|
|
B cells (CD19/CD20 positive cells) and T cells (CD3/CD4/CD8 positive cells)
기간: Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.
|
Summary statistics of B cells and T cells will be calculated to monitor changes over time. |
Assessments will be conducted at baseline and at Weeks 1, 12, 24, 25, 36, and 48.
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Tomoko Okamoto, MD, National Center of Neurology and Psychiatry
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .